Arvinas, Inc. (NASDAQ:ARVN) Expected to Post FY2027 Earnings of $4.78 Per Share

Arvinas, Inc. (NASDAQ:ARVN) – Analysts at HC Wainwright upped their FY2027 earnings per share estimates for shares of Arvinas in a research report issued on Wednesday, November 8th. HC Wainwright analyst A. Fein now expects that the company will earn $4.78 per share for the year, up from their previous forecast of $4.63. HC Wainwright has a “Buy” rating and a $90.00 price objective on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($6.05) per share.

Several other research analysts have also recently issued reports on ARVN. Stifel Nicolaus lowered their price objective on Arvinas from $46.00 to $42.00 and set a “buy” rating for the company in a research report on Wednesday. Piper Sandler lowered their price objective on Arvinas from $70.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, October 23rd. Oppenheimer reaffirmed an “outperform” rating and set a $95.00 price objective on shares of Arvinas in a research report on Wednesday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $70.00 price objective on shares of Arvinas in a research report on Thursday, September 7th. Finally, Wedbush raised Arvinas from a “neutral” rating to an “outperform” rating and lowered their price objective for the stock from $27.00 to $24.00 in a research report on Monday, October 23rd. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, Arvinas has an average rating of “Moderate Buy” and a consensus target price of $57.14.

Arvinas Price Performance

Shares of NASDAQ ARVN opened at $15.16 on Thursday. The stock’s 50-day moving average is $19.98 and its two-hundred day moving average is $23.20. The company has a market cap of $810.91 million, a price-to-earnings ratio of -2.74 and a beta of 1.86. Arvinas has a 1-year low of $13.57 and a 1-year high of $57.96.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($1.18) earnings per share for the quarter, topping the consensus estimate of ($1.58) by $0.40. Arvinas had a negative return on equity of 57.56% and a negative net margin of 185.09%. The company had revenue of $34.60 million for the quarter, compared to the consensus estimate of $39.58 million. During the same quarter in the prior year, the business earned ($1.24) EPS. Arvinas’s revenue was up 14.2% on a year-over-year basis.

Institutional Trading of Arvinas

A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC raised its stake in shares of Arvinas by 1.0% during the 1st quarter. FMR LLC now owns 5,718,031 shares of the company’s stock worth $156,217,000 after buying an additional 58,561 shares in the last quarter. BlackRock Inc. raised its stake in shares of Arvinas by 9.6% during the 2nd quarter. BlackRock Inc. now owns 4,903,469 shares of the company’s stock worth $121,704,000 after buying an additional 427,871 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Arvinas by 2.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,180,065 shares of the company’s stock worth $185,971,000 after buying an additional 116,877 shares in the last quarter. EcoR1 Capital LLC raised its stake in shares of Arvinas by 19.0% during the 1st quarter. EcoR1 Capital LLC now owns 3,717,788 shares of the company’s stock worth $101,570,000 after buying an additional 594,488 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Arvinas by 5.2% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,267,570 shares of the company’s stock worth $137,532,000 after buying an additional 160,860 shares in the last quarter. 86.33% of the stock is owned by institutional investors and hedge funds.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.